Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes
Study assessing efficacy of a Cisplatine- Métronomic cyclophosphamide treatment in Patients with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxanes.
Metastatic Breast Cancer
DRUG: Cisplatin|DRUG: Cyclophosphamide
Response rate of cisplatine - metronomic cyclophosphamide treatment, 12 months and 6 weeks
Disease free progression, 3 years|Safety profile of cisplatin - metronomic cyclophosphamide association, Number of Participants with Adverse Events, 12 months and 6 weeks|Overall survival, 5 years|Predictive factors to response and/or resistance treatment, 12 months and 6 weeks
Study assessing efficacy of a Cisplatine- Métronomic cyclophosphamide treatment in Patients with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxanes.